Disturbances in sensory neurons may alter transient pain into chronic pain
University Medical Center UtrechtTransient inflammatory pain causes long-lasting mitochondrial changes in sensory neurons, contributing to chronic pain.
Transient inflammatory pain causes long-lasting mitochondrial changes in sensory neurons, contributing to chronic pain.
New hope for other nervous system disorders like ALS
Forward Therapeutics, Inc., a biopharmaceutical company developing next-generation small molecule therapies for chronic immunological and inflammatory disorders, today announced a $50 million Series A financing.
Children’s Hospital Los Angeles has launched a new clinical trial to investigate a potential treatment for Dup15q syndrome, a rare genetic condition that causes developmental delays, autism spectrum disorder and epilepsy.
In a proof-of-concept in ACS’ Nano Letters, a team has designed injectable nanoparticles that released naloxone ― which rapidly reverses opioid overdose effects ― when triggered by blue light. In experiments with mice, this system was activated a month after injection.
New research in the November 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network suggests that breast cancer patients who have insufficient levels of vitamin D before starting paclitaxel treatment are more likely to experience peripheral neuropathy.
Scientists find the use of oral contraceptives may affect fear-related brain morphology, knowledge that could deepen understanding of fear-related mechanisms that primarily affect women
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that BioReference® Health, LLC, an OPKO Health, Inc. company and full-service laboratory that processes more than 12 million tests annually, will implement SOPHiA GENETICS' technology and add MSK-ACCESS® liquid biopsy to its test suite.
MD Anderson and Jazz Pharmaceuticals announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz’s investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.
Value in Health announced the publication of a study showing that United States Medicare could save up to an additional $5-$10 billion dollars annually across 10 drugs if it negotiated prices using a therapeutic reference pricing approach rather than using the statutory ceiling price alone.
Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeted therapies based on its proprietary Alluminox™ platform today announced the presentation of two posters of AI-based analyses at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held November 3-5, 2023, in San Diego, CA (SITC 2023).
A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia and Non-Hodgkin lymphoma whose disease has stopped responding to standard treatments.
Researchers combined the features of clinical drugs to treat hepatitis C and viruses similar to COVID-19. This allowed them to synthesize BBH-1, a promising inhibitor that targets the breakdown of the SARS-CoV-2 virus. The researchers characterized samples using X-ray and neutron diffraction techniques to provide atomic-level insights on the structure of the BBH-1 inhibitor and how it binds to the SARS-CoV-2 protein.
By leveraging the power of oxygen, these gelatin patches can act as effective tissue adhesives that accelerate the healing of wounds
The ERP Biomarker Qualification Consortium announced today that they will be presenting data from a recently completed, pharma industry sponsored study that measured the electrophysiologic effects of ketamine on healthy brain function, at the CNS Summit 2023 in Boston.
Antibiotic-resistant bacteria pose a major challenge to healthcare systems worldwide. Due to numerous resistance mechanisms, infections with the pathogen Pseudomonas aeruginosa are particularly feared. Researchers at the German Center for Infection Research (DZIF), the University Hospital Cologne, the Helmholtz Centre for Infection Research in Braunschweig and the University Medical Center Hamburg-Eppendorf have now discovered antibodies that could lead to a highly potent treatment option of acute and chronic infections with P. aeruginosa. The study was published in the prestigious scientific journal Cell.
A new Cochrane review has found that insulin can be kept at room temperature for months without losing potency, offering hope to people living with diabetes in regions with limited access to healthcare or stable powered refrigeration
Cancer drug could treat inflammatory diseases by calming down the inflammatory response
FragDPI, a novel drug-protein interaction prediction method, outperforms baselines and identifies specific interaction parts, aiding drug discovery
In an invited commentary, Kathleen Mulvaney, assistant professor with the Fralin Biomedical Research Institute at VTC, talks about the potential of a new drug that has shown early promise in clinical trials for solid tumors by killing cancer cells that lack specific tumor suppressor genes.
Canadian Cardiovascular Society consensus statement published in the Canadian Journal of Cardiology paves the way for refining treatment and providing individualized care
An international research team, including Jonathan C. Schisler, PhD, in the UNC School of Medicine, has found how SARS-CoV-2 causes widespread “energy outages” throughout major organs, and how these effects contribute to debilitating long COVID symptoms.
A new drug developed by professors from the School of Pharmacy and Pharmaceutical Sciences at Binghamton University, State University of New York has received FDA approval for the treatment of patients with Duchenne muscular dystrophy, a common genetic disease that mostly affects young boys.
Joseph A. Barone, Dean of the Rutgers University Ernest Mario School of Pharmacy, has been selected as the 2023 recipient of the New Jersey Pharmacists Association Lifetime Achievement Award
In August 2022, a New York Times article highlighted an off-label use of a drug that remedies a type of hair loss. The subsequent media attention led to a surge in interest in the drug known as Minoxidil. Researchers at the George Washington University surveyed pharmacies in the Washington, Maryland and Virginia metro area and found shortages in thirty day supplies of the drug.
UC San Diego engineers have developed modular nanoparticles that can be easily customized to target different biological entities such as tumors, viruses or toxins. The surface of the nanoparticles is engineered to host any biological molecules of choice, making it possible to tailor the nanoparticles for a wide array of applications, ranging from targeted drug delivery to neutralizing biological agents.
Rutgers teams up with four other universities to form a new research center in Piscataway.
A new large-scale study led by researchers at the University of Cincinnati and Northwell Health, New York's largest health care provider, found the drug metformin can help prevent or reduce weight gain in youth taking medication to treat bipolar disorder.
Nagoya University researchers used AI to design and synthesize a new, highly effective gastric acid inhibitor, demonstrating the potential of AI in pharmaceutical development.
Offers new option with improved quality of life for patients with moderate-to-severely active disease.
A new study from the University of Wisconsin–Madison suggests that chemotherapy may not be reaching its full potential, in part because researchers and doctors have long misunderstood how some of the most common cancer drugs actually ward off tumors.
A four-year, $3.4 million grant to investigate molecular mechanisms and therapeutic treatments for acute respiratory distress syndrome (ARDS) has been awarded to UTHealth Houston researchers by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health.
The Palliative Care Program at Johns Hopkins Bayview Medical Center, consisting of an interprofessional team of clinicians and researchers from Bayview and Johns Hopkins Schools of Nursing, Public Health, and Medicine, received the 2023 Circle of Life Award from the American Hospital Association.
The discovery of a physical interaction between two proteins in brain cells that can be traced in mice to control of movement, anxiety and memory could one day open the door to development of new schizophrenia treatment strategies, researchers say.
A new research study shows that cerebrospinal fluid reduces current treatment efficacy in brain cancer and identifies new therapeutic opportunities.
A study spearheaded by Oregon State University has shown why certain polyunsaturated fatty acids work to combat a dangerous liver condition, opening a new avenue of drug research for a disease that currently has no FDA-approved medications.
This cutting-edge technique activates a specific neurotransmitter receptor using mid-infrared light, which can penetrate deep into tissue and offers unparalleled pharmacological and spatiotemporal precision in three dimensions.
The world’s largest trial of multiple interventions for critically ill adults with COVID-19 has simultaneously released results about two of its treatments, vitamin C and simvastatin
A course of treatment with existing drugs prior to chemoradiation led to a 35% reduction in the risk of death or return of cancer, in trial results presented by researchers from UCL and UCLH.
Cabozantinib, which targets tumor cell growth and tumor blood vessel growth, sharply improved progression-free survival over placebo in patients with extra-pancreatic and pancreatic neuroendocrine tumors
A broad-spectrum antiviral drug candidate, 2-thiouridine, that targets positive-strand RNA viruses has been identified and characterized.
In study after study, the psychoactive drug ketamine has given profound and fast relief to many people suffering from severe depression.
New research reveals that the nation’s most widely prescribed type of sedative may be less effective than clinicians and scientists have been led to believe, based on publications in medical journals.
A first-of-its kind hormone replacement therapy that more closely replicates the natural circadian and ultradian rhythms of our hormones has shown to improve symptoms in patients with adrenal conditions. Results from the University of Bristol-led clinical trial are published today [20 October] in the Journal of Internal Medicine.
In a first-of-its-kind study, researchers from the University of California, Irvine have discovered an extraordinary surge in the utilization of weight loss-associated GLP-1 receptor agonists, a class of medications commonly used in the treatment of Type 2 diabetes and obesity, that is poised to accelerate, based on emerging clinical evidence.
Scientists have showed that medicine on the base of vitamin B6 can be used for treatment of post-COVID asthenia – condition when patients complain of rapid fatigability, problems with memory and sleep. Taking of this product enabled 35% patients to improve memory, 40% patients began to sleep well, 42% of people began to get tired more slowly. Besides this taking this medicine enabled patients to experience physical activity easier. Results of the research are published in Magazine of Infectology.
Scientists at Tufts University School of Medicine have developed a genome-scale metabolic model or “subway map” of key metabolic activities of the bacterium that causes Lyme disease.